A Phase I/II open-label trial of intravenous allogeneic mesenchymal stromal cell therapy in adults with recessive dystrophic epidermolysis bullosa.
Sign Up to like & getrecommendations! Published in 2019 at "Journal of the American Academy of Dermatology"
DOI: 10.1016/j.jaad.2019.11.038
Abstract: BACKGROUND Recessive dystrophic epidermolysis bullosa (RDEB) is a hereditary blistering disorder due to lack of type VII collagen (C7). At present, treatment is mainly supportive. OBJECTIVE To determine whether intravenous allogeneic bone marrow-derived mesenchymal stromal/stem… read more here.
Keywords: intravenous allogeneic; label; recessive dystrophic; dystrophic epidermolysis ... See more keywords